Literature DB >> 11877589

Survival after end-stage renal disease in autosomal dominant polycystic kidney disease.

Costas Fourtounas, Vasilis Panteris, Dimitrios Valis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877589     DOI: 10.1053/ajkd.2002.32161

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  5 in total

1.  Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease.

Authors:  Miklos Z Molnar; Lilia R Lukowsky; Elani Streja; Ramanath Dukkipati; Jennie Jing; Allen R Nissenson; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Hypertens       Date:  2010-12       Impact factor: 4.844

2.  Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease.

Authors:  Lilia R Lukowsky; Miklos Z Molnar; Joshua J Zaritsky; John J Sim; Istvan Mucsi; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2011-12-29       Impact factor: 5.992

3.  Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease.

Authors:  Parta Hatamizadeh; Vanessa Ravel; Lilia R Lukowsky; Miklos Z Molnar; Hamid Moradi; Kevin Harley; Madeline Pahl; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2013-11       Impact factor: 5.992

4.  Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry.

Authors:  Víctor Martínez; Jordi Comas; Emma Arcos; Joan Manel Díaz; Salomé Muray; Juan Cabezuelo; José Ballarín; Elisabet Ars; Roser Torra
Journal:  BMC Nephrol       Date:  2013-09-05       Impact factor: 2.388

5.  Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival.

Authors:  Kevin C Abbott; Lawrence Y Agodoa
Journal:  BMC Nephrol       Date:  2002-08-23       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.